Shots:
- The CHMP has recommended EURneffy 1mg (adrenaline nasal spray) to treat allergic reactions as well as idiopathic or exercise-induced anaphylaxis in children (≥4yrs. & 15-30kg)
- If granted, the approval would be valid in all 30 EEA states & will support an extension to the existing EURneffy 2 mg’s approval from Aug 2024 for emergency anaphylaxis treatment in adults & children (≥30kg)
- In Nov 2024, ARS Pharma granted ALK exclusive rights to commercialize EURneffy in the EU & other markets (except US (under brand name neffy), Australia, New Zealand, Japan, & China. In May 2025, the deal extended to US co-promotion
Ref: Globenewswire | Image: ALK |Press Release
Related News: ARS Pharmaceuticals and ALK’s EURneffy Secures the MHRA’s Approval to Treat Allergic Reactions in Children
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
